(New York Times) – The Food and Drug Administration has taken a crucial step toward expanding access to the antipsychotic medication clozapine, the only drug approved for treatment-resistant schizophrenia, among the most devastating of mental illnesses.

The agency announced on Monday that it was eliminating a requirement that patients submit blood tests before their prescriptions can be filled. (Read More)